Global Evaluation of the Interstitial Lung Disease (ILD) Diagnostic Pathway in the Post-COVID Era (ILD vMDT)

First published: 01/06/2022

Last updated: 08/08/2024

Study Finalised

Administrative details

EU PAS number

EUPAS47537

Study ID

47538

DARWIN EU® study

No

Study countries

- Argentina
- Australia
- Austria
- Belgium

- Brazil
- Canada
- Chile
- Croatia
- Denmark
- Ecuador
- Egypt
- Finland
- France
- Germany
- Greece
- India
- Indonesia
- Ireland
- Italy
- Japan
- Luxembourg
- Malaysia
- Mexico
- New Zealand
- Norway
- Peru
- Poland
- Portugal
- Romania
- Singapore
- South Africa
- Spain
- Sweden
- Switzerland

Türkiye
United Kingdom
United Kingdom (Northern Ireland)
United States

Study description

This study aims to identify characteristics of fibrotic interstitial lung disease (ILD) diagnostic practice and the features, strengths and limitations of distanced virtual multi-disciplinary team (vMDT) meetings, and open discussion on the prevalence of post-COVID fibrosis. An on-line survey will be sent via email to dedicated and non-dedicated ILD centres and countries within both mature and expanding economies (featuring a wide range of health systems and health infrastructures) across key global regions. The study will take an inclusive approach, welcoming responses from all countries and participants involved in the diagnosis of ILD.

Study status

Finalised

Research institutions and networks

Networks

Respiratory Effectiveness Group (REG)

Belgium
Denmark
France
Germany

Greece
Hungary
Italy
Netherlands
Spain
Sweden
United Kingdom

First published: 07/07/2021

Last updated: 04/06/2024

Network | ENCePP partner

Contact details

Study institution contact

Lough Graham enquiries@regresearchnetwork.org

Study contact

enquiries@regresearchnetwork.org

Primary lead investigator

Lough Graham

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 19/05/2022

Actual: 19/05/2022

Study start date
Planned: 20/05/2022

Actual: 20/05/2022

Data analysis start date
Planned: 23/05/2022

Actual: 24/05/2022

Date of interim report, if expected
Planned: 23/05/2022

Actual: 25/05/2022

Date of final study report
Planned: 31/05/2022

Actual: 31/05/2022

Sources of funding

- Pharmaceutical company and other private sector

More details on funding

Boehringer Ingelheim

Study protocol

REG ILD eMDT protocol REG-RES2021 v1.pdf (2.06 MB)

Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Methodological aspects

Study type

Study type list

Study topic:

Other

Study topic, other:

Disease/Epidemiology study

Study type:

Non-interventional study

Scope of the study:

Other

If ‘other’, further details on the scope of the study

Descriptive analysis of ILD diagnostic pathway

Data collection methods:

Primary data collection

Main study objective:

This study aims to identify characteristics of fibrotic interstitial lung disease (ILD) diagnostic practice and the features, strengths and limitations of distanced virtual multi-disciplinary team (vMDT) meetings, and open discussion on the prevalence of post-COVID fibrosis.

Study Design

Non-interventional study design

Other

Non-interventional study design, other

Electronic systematic survey

Population studied

Short description of the study population

The study focused on interstitial lung disease (ILD) MDTs or eMDTs diagnoses center.

Age groups

- Adults (18 to < 46 years)
- Adults (46 to < 65 years)
- Adults (75 to < 85 years)
- Adults (85 years and over)

Estimated number of subjects

400

Study design details

Data analysis plan

Descriptive statistics, Mann-Whitney U tests, Kruskal-Wallis tests, Chi2 or Fischer’s exact tests (as appropriate).

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data sources (types)

Other

Data sources (types), other

An online survey will be sent to ILD centres for a representative to complete. There is no data on patients collected.

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No